Leukemia stem cells are a rare subpopulation of cells within the leukemia that are responsible for long-term disease maintenance and relapse. Our goal is to better characterize these cells to find ways to target and eliminate them and improve patient outcomes. Cancer stem cells, including leukemia stem cells, exist in a state of quiescence or slow growth, which may enable them to escape anti-proliferative cancer treatments.
Understanding cellular quiescence will help identify potential vulnerabilities of leukemia stem cells, and new ways to target them. Using this protocol, we can identify and isolate quiescent leukemia cells from a zebrafish model of T-cell acute lymphoblastic leukemia. Those cells can be used for downstream applications, such as in vivo drug screening, transcriptomic profiling, and proteomics analysis.
